|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2003-2-4
|
|
pubmed:abstractText |
To evaluate the efficacy and toxicity of concurrent administration of doxorubicin and docetaxel, without prophylactic use of granulocyte colony-stimulating factor, as first-line chemotherapy in patients with metastatic breast cancer (MBC).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0030-2414
|
|
pubmed:author |
pubmed-author:AiharaTomohikoT,
pubmed-author:DEVEFF,
pubmed-author:HirakiShunkichiS,
pubmed-author:HorikoshiNoboruN,
pubmed-author:ItohKuniakiK,
pubmed-author:KatsumataNoriyukiN,
pubmed-author:NoguchiShinzaburoS,
pubmed-author:SasakiYasutsunaY,
pubmed-author:SonooHiroshiH,
pubmed-author:TabeiToshioT,
pubmed-author:TakatsukaYuichiY,
pubmed-author:WatanabeToruT
|
|
pubmed:copyrightInfo |
Copyright 2003 S. Karger AG, Basel
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
64
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
124-30
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:12566909-Adult,
pubmed-meshheading:12566909-Aged,
pubmed-meshheading:12566909-Antibiotics, Antineoplastic,
pubmed-meshheading:12566909-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:12566909-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:12566909-Breast Neoplasms,
pubmed-meshheading:12566909-Disease Progression,
pubmed-meshheading:12566909-Doxorubicin,
pubmed-meshheading:12566909-Drug Administration Schedule,
pubmed-meshheading:12566909-Female,
pubmed-meshheading:12566909-Humans,
pubmed-meshheading:12566909-Injections, Intravenous,
pubmed-meshheading:12566909-Middle Aged,
pubmed-meshheading:12566909-Neoplasm Staging,
pubmed-meshheading:12566909-Paclitaxel,
pubmed-meshheading:12566909-Taxoids,
pubmed-meshheading:12566909-Treatment Failure,
pubmed-meshheading:12566909-Treatment Outcome
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Phase II study of concurrent administration of doxorubicin and docetaxel as first-line chemotherapy for metastatic breast cancer.
|
|
pubmed:affiliation |
Department of Surgery, Kansai Rosai Hospital, Hyogo, Japan. aiharat@kanrou.net
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
